Share Name Share Symbol Market Type Share ISIN Share Description
International Biotechnology Trust Plc LSE:IBT London Ordinary Share GB0004559349 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  12.00 1.94% 632.00 626.00 632.00 634.00 626.00 630.00 64,620 16:25:07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 0.0 -2.5 -6.9 - 241

International Biotechnol... Share Discussion Threads

Showing 226 to 248 of 500 messages
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
DateSubjectAuthorDiscuss
05/3/2013
12:35
NAV Monday 04 Mar Ex Income 264.17
davebowler
20/2/2013
10:17
V good value.
philo124
19/2/2013
11:05
Monday 18 Feb NAV Ex Income 252.37
davebowler
12/2/2013
14:43
NAV c248p.
philo124
29/1/2013
12:56
Date NAV Pence Monday 28 Jan Ex Income 251.45
davebowler
21/1/2013
18:51
Yep, agreed sit it with a chunky of GSK to balance yield.
philo124
21/1/2013
17:15
one for my Sipp, ticks the boxes, performance, discount and prepared to ignore the yield
127tolmers
19/1/2013
22:21
http://www.ibtplc.com/assets/images/IBT%20Presentation%20AGM_05Dec12.pdf
davebowler
19/1/2013
22:17
http://www.ibtplc.com/fact_sheets/2012/December2012.pdf
davebowler
17/1/2013
13:46
BIOG is at a 1% premium http://www.trustnet.com/Factsheets/Factsheet.aspx?fundCode=AKFR0&univ=T whereas IBT (similar) is at a 16% discount.http://www.trustnet.com/Factsheets/Factsheet.aspx?fundCode=ITIBT&univ=T
davebowler
13/12/2012
16:52
Bought for SIPP; already hold BIOG & PCGH.
philo124
07/12/2012
14:17
http://www.edisoninvestmentresearch.co.uk/sectorreports/HealthcareQuarterly_Dec12.pdf
davebowler
26/11/2012
14:42
Ridiculously cheap at 17% discount to NAV compared to similar BIOG at 5% discount.
davebowler
23/11/2012
16:55
Why the recent decline in the s.p.? Profit taking?
gilston
19/10/2012
13:22
Good results today persuaded me to buy. A few key bits. "Investment Performance In this, my first letter to shareholders as Chairman, I am pleased to report to you a substantial positive return for the year ended 31 August 2012. The NAV increased by 41.9% to 232.5p per share. With a small narrowing of the discount to 12.0% from 12.7%, the Company's share price increased by 43.0%. By comparison, the FTSE All-Share Index produced a total return of just 10.2% over the same period. For the first time in several years, positive absolute performance was generated from both the quoted and unquoted parts of the portfolio, with a 47.8% and 21.7% increase for each, respectively. Investor enthusiasm for the biotechnology sector improved dramatically over the period against the backdrop of positive, yet muted, price gains for the broader stock market. With the Company's share price currently trading at a 12.0% discount to NAV, and the unquoted portfolio comprising 16.0% of overall NAV, the market is assigning little value to the unquoted portfolio. The Board believes this represents a valuation anomaly and offers investors an excellent opportunity to become Shareholders in the biotechnology industry's quiet revolution, even after the quoted sector's recent very strong run. The Company currently recognises GBP0.7m of fair value for future milestone payments potentially due to the Company from unquoted investments already exited. The receipt of these payments is contingent on pre-agreed, and legally-binding, operational or clinical development milestones being achieved. If paid in full, these milestone payments would amount to GBP9.6m on current exchange rates, representing GBP8.8m of additional unrecognised value."
127tolmers
27/9/2012
10:54
Bullish outlook; http://www.internationalbiotrust.com/press_releases/Biotech.pdf
davebowler
27/9/2012
10:53
I stand corrected -I only looked at the last 5 years!Presumably they peaked in the 'Tech' bubble.
davebowler
25/9/2012
14:12
Dave I wish this was all time high bought these about 10 years ago at around £3 I think they peaked just shy of £4 should have sold then. Holding since hoping they would come good one day. Only needs one good IPO and asset value will fly.
gallops
24/9/2012
15:35
All time high- Friday 21 Sep NAV Ex Income 243.95
davebowler
28/6/2012
12:23
All time high. http://www.fundweb.co.uk/investment-trusts/news/nick-train-we%E2%80%99re-at-the-start-of-massive-tech-bull-market/1053754.article
davebowler
01/6/2012
15:39
NAV Thursday 31 May Ex Income 221.32
davebowler
09/5/2012
14:55
NAV Tuesday 08 May Excluding Income 216.05
davebowler
27/4/2012
09:27
Portfolio Update The Board of International Biotechnology Trust plc (the "Company") notes that today a definitive agreement has been signed by Jazz Pharmaceuticals (NASDAQ:JAZZ) to buy the unquoted portfolio company EUSA Pharma for $650m in cash plus a potential $50m milestones payment. The Director's have changed the valuation of the Company's interest in EUSA Pharma by £1.9m from £2.7m to £4.6m on a cost of £2.4m to reflect the terms of the deal. This change in valuation will be included in the Company's Net Asset Value from today and will be released to the market on Monday. The increase to NAV per share in comparison to that released yesterday is 3.5 pence per share. Enquiries: Kate Bingham/David Pinniger Telephone: 020 7412 7070
davebowler
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
Your Recent History
LSE
IBT
Internatio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200118 11:09:16